Asia FX dithers as dollar steadies before Powell speech; yen muted after CPI data
Christine Ring, Chief Legal Officer of Nurix Therapeutics, Inc. (NASDAQ:NRIX), sold 3,841 shares of common stock on July 30, 2025, to cover tax withholding obligations. The shares were sold at a weighted average price of $12.011, resulting in a total transaction value of $46,134. The price per share ranged from $11.78 to $12.315. The transaction occurred as the stock trades near $11.88, significantly below its 52-week high of $29.56, with InvestingPro analysis indicating the stock is currently undervalued.
On the same day, Ring also acquired a total of 10,532 shares of Nurix Therapeutics common stock through the vesting of restricted stock units. These transactions involved 1,924 shares, 2,000 shares, 3,750 shares, and 2,858 shares, all at a price of $0.
Following these transactions, Ring directly owns 44,009 shares of Nurix Therapeutics.
In other recent news, Nurix Therapeutics has been the subject of several analyst updates following its second-quarter results. Morgan Stanley (NYSE:MS) adjusted its price target for Nurix to $16, citing higher anticipated spending for planned pivotal trials, while maintaining an Equalweight rating. UBS also lowered its price target to $26 from $30, attributing the change to increased operational expenses. Despite these adjustments, Stifel remains optimistic, maintaining a Buy rating with a $35 price target, projecting potential peak sales of $4.5 billion for Nurix’s lead drug candidate. Goldman Sachs initiated coverage with a Buy rating and set an ambitious price target of $182, expecting the Crenessity drug launch to counter potential challenges in the growth of Ingrezza. Stifel reiterated its Buy rating, emphasizing expectations for Nurix to announce development plans for its drug candidate bexobrutideg by late 2025. These developments reflect a range of perspectives on Nurix’s financial and strategic outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.